View this program in its entirety here: [ Ссылка ]
As Omicron subvariants continue to emerge, clinical practice must quickly shift to optimally manage nonhospitalized patients with mild to moderate COVID-19. The current Omicron subvariants have left only 1 anti-SARS-CoV-2 monoclonal antibody for pre-exposure prophylaxis and 1 for treatment. Drs. Lucy Horton and Monica Gandhi discuss what they are doing to incorporate both antivirals and anti-SARS-CoV-2 monoclonal antibodies into practice.
For more information, visit our clinical resource center: [ Ссылка ]
